Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL JANUS KINASES (JAKS) INHIBITOR DRUGS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL JANUS KINASES (JAKS) INHIBITOR DRUGS SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL JANUS KINASES (JAKS) INHIBITOR DRUGS MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES MODEL
5 INDUSTRY INSIGHTS
5.1 PATENT ANALYSIS
5.1.1 PATENT LANDSCAPE
5.1.2 USPTO NUMBER
5.1.3 PATENT EXPIRY
5.1.4 EPIO NUMBER
5.1.5 PATENT STRENGTH AND QUALITY
5.1.6 PATENT CLAIMS
5.1.7 PATENT CITATIONS
5.1.8 PATENT LITIGATION AND LICENSING
5.1.9 FILE OF PATENT
5.1.10 PATENT RECEIVED CONTRIES
5.1.11 TECHNOLOGY BACKGROUND
5.2 DRUG TREATMENT RATE BY MATURED MARKETS
5.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
5.4 PATIENT FLOW DIAGRAM
5.5 KEY PRICING STRATEGIES
5.6 KEY PATIENT ENROLLMENT STRATEGIES
5.7 INTERVIEWS WITH SPECIALIST
5.8 OTHER KOL SNAPSHOTS
6 MERGERS AND ACQUISITION
6.1 LICENSING
6.2 COMMERCIALIZATION AGREEMENTS
7 REGULATORY FRAMEWORK
7.1 REGULATORY APPROVAL PROCESS
7.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
7.3 REGULATORY APPROVAL PATHWAYS
7.4 LICENSING AND REGISTRATION
7.5 POST-MARKETING SURVEILLANCE
7.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
8 PIPELINE ANALYSIS
8.1 CLINICAL TRIALS AND PHASE ANALYSIS
8.2 DRUG THERAPY PIPELINE
8.3 PHASE III CANDIDATES
8.4 PHASE II CANDIDATES
8.5 PHASE I CANDIDATES
8.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved But Not Yet Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE
Technology Preclinical/ Research Project
JANUS KINASES (JAKS) INHIBITOR DRUGS XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR JANUS KINASES (JAKS) INHIBITOR DRUGS
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
9 MARKETED DRUG ANALYSIS
9.1 DRUG
9.1.1 BRAND NAME
9.2 THERAPEUTIC INDIACTION
9.3 PHARACOLOGICAL CLASS OD THE DRUG
9.4 DRUG PRIMARY INDICATION
9.5 MARKET STATUS
9.6 DRUG DOSAGES FORM
9.7 DOSAGES AVAILABILITY
9.8 PACKAGING TYPE
9.9 DRUG ROUTE OF ADMINISTRATION
9.1 DOSING FREQUENCY
9.11 DRUG INSIGHT
9.12 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
9.12.1 FORECAST MARKET OUTLOOK
9.12.2 CROSS COMPETITION
9.12.3 THERAPEUTIC PORTFOLIO
9.12.4 CURRENT DEVELOPMENT SCENARIO
10 MARKET ACCESS
10.1 10-YEAR MARKET FORECAST
10.2 CLINICAL TRIAL RECENT UPDATES
10.3 ANNUAL NEW FDA APPROVED DRUGS
10.4 DRUGS MANUFACTURER AND DEALS
10.5 MAJOR DRUG UPTAKE
10.6 CURRENT TREATMENT PRACTICES
10.7 IMPACT OF UPCOMING THERAPY
11 R & D ANALYSIS
11.1 COMPARATIVE ANALYSIS
11.2 DRUG DEVELOPMENTAL LANDSCAPE
11.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
11.4 THERAPEUTIC ASSESSMENT
11.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
12 MARKET OVERVIEW
12.1 DRIVERS
12.2 RESTRAINTS
12.3 OPPORTUNITIES
12.4 CHALLENGES
13 GLOBAL JANUS KINASES (JAKS) INHIBITOR DRUGS MARKET, BY DRUGS
13.1 OVERVIEW
13.2 MARKETED DRUG
13.2.1 GENERIC
13.2.1.1. TOFACITINIB
13.2.1.2. BARICITINIB
13.2.1.3. RUXOLITINIB
13.2.1.4. UPADACITINIB
13.2.1.5. FEDRATINIB
13.2.1.6. RUXOLITINIB
13.2.1.7. OTHERS
13.2.2 BRANDED
13.2.2.1. XELJANZ
13.2.2.2. OLUMIANT
13.2.2.3. JAKAFI
13.2.2.4. RINVOQ
13.2.2.5. INREBIC
13.2.2.6. CIBINQO
13.2.2.7. OTHERS
13.3 EMERGING DRUGS/PIPELINE DRUGS
13.3.1 FILGOTINIB (GLPG0634)
13.3.2 PEFICITINIB (ASP015K)
13.3.3 ITACITINIB (INCB039110)
13.3.4 ABROCITINIB (PF-04965842)
13.3.5 OTHERS
14 GLOBAL JANUS KINASES (JAKS) INHIBITOR DRUGS MARKET, BY APPLICATION
14.1 OVERVIEW
14.2 AUTOIMMUNE CONDITION
14.2.1 PSORIATIC ARTHRITIS
14.2.2 ULCERATIVE ARTHRITIS
14.2.3 RHEUMATOID ARTHRITIS
14.2.4 ANKYLOSING SPONDYLITIS
14.2.5 OTHERS
14.3 BLOOD DISORDER
14.3.1 MYELOFIBROSIS
14.3.2 POLYCYTHEMIA VERA
14.3.3 GRAFT-VERSUS-HOST DISEASE (GVHD)
14.3.4 OTHERS
14.4 ULCERATIVE COLITIS
14.5 SKIN DISEASE
14.5.1 ATOPIC DERMATITIS
14.5.2 ALOPECIA AREATA
14.5.3 OTHERS
14.6 OTHERS
15 GLOBAL JANUS KINASES (JAKS) INHIBITOR DRUGS MARKET, BY DRUG TYPE
15.1 BRANDED
15.1.1 XELJANZ
15.1.2 OLUMIANT
15.1.3 JAKAFI
15.1.4 RINVOQ
15.1.5 INREBIC
15.1.6 CIBINQO
15.1.7 OTHERS
15.2 GENERIC
16 GLOBAL JANUS KINASES (JAKS) INHIBITOR DRUGS MARKET, BY TYPE
16.1 JAK1 INHIBITOR
16.2 JAK2 INHIBITOR
16.3 JAK3 INHIBITOR
16.4 OTHERS
17 GLOBAL JANUS KINASES (JAKS) INHIBITOR DRUGS MARKET, BY DOSAGE FORM
17.1 OVERVIEW
17.2 IMMEDIATE-RELEASE (IR) TABLET
17.3 EXTENDED-RELEASE (ER) TABLET
17.4 ORAL LIQUID
18 GLOBAL JANUS KINASES (JAKS) INHIBITOR DRUGS MARKET, BY AGE GROUP
18.1 OVERVIEW
18.2 PEDIATRICS
18.3 ADULTS
18.4 GERIATRICS
19 GLOBAL JANUS KINASES (JAKS) INHIBITOR DRUGS MARKET, BY GENDER
19.1 OVERVIEW
19.2 MALE
19.3 FEMALE
20 GLOBAL JANUS KINASES (JAKS) INHIBITOR DRUGS MARKET, BY END USER
20.1 OVERVIEW
20.2 HOSPITAL
20.3 SPECIALTY CLINICS
20.4 HOME HEALTHCARE
20.5 OTHERS.
21 GLOBAL JANUS KINASES (JAKS) INHIBITOR DRUGS MARKET, BY DISTRIBUTION CHANNEL
21.1 OVERVIEW
21.2 RETAIL PHARMACIES
21.3 HOSPITAL PHARMACIES
21.4 ONLINE PHARMACIES
21.5 OTHERS
22 GLOBAL JANUS KINASES (JAKS) INHIBITOR DRUGS MARKET, SWOT AND DBMR ANALYSIS
23 GLOBAL JANUS KINASES (JAKS) INHIBITOR DRUGS MARKET, COMPANY LANDSCAPE
23.1 COMPANY SHARE ANALYSIS: GLOBAL
23.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
23.3 COMPANY SHARE ANALYSIS: EUROPE
23.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
23.5 MERGERS & ACQUISITIONS
23.6 NEW PRODUCT DEVELOPMENT & APPROVALS
23.7 EXPANSIONS
23.8 REGULATORY CHANGES
23.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
24 GLOBAL JANUS KINASES (JAKS) INHIBITOR DRUGS MARKET, BY REGION
Global JANUS KINASES (JAKS) INHIBITOR DRUGS Market, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
24.1 NORTH AMERICA
24.1.1 U.S.
24.1.2 CANADA
24.1.3 MEXICO
24.2 EUROPE
24.2.1 GERMANY
24.2.2 U.K.
24.2.3 ITALY
24.2.4 FRANCE
24.2.5 SPAIN
24.2.6 RUSSIA
24.2.7 SWITZERLAND
24.2.8 TURKEY
24.2.9 BELGIUM
24.2.10 NETHERLANDS
24.2.11 DENMARK
24.2.12 SWEDEN
24.2.13 POLAND
24.2.14 NORWAY
24.2.15 FINLAND
24.2.16 REST OF EUROPE
24.3 ASIA-PACIFIC
24.3.1 JAPAN
24.3.2 CHINA
24.3.3 SOUTH KOREA
24.3.4 INDIA
24.3.5 SINGAPORE
24.3.6 THAILAND
24.3.7 INDONESIA
24.3.8 MALAYSIA
24.3.9 PHILIPPINES
24.3.10 AUSTRALIA
24.3.11 NEW ZEALAND
24.3.12 VIETNAM
24.3.13 TAIWAN
24.3.14 REST OF ASIA-PACIFIC
24.4 SOUTH AMERICA
24.4.1 BRAZIL
24.4.2 ARGENTINA
24.4.3 REST OF SOUTH AMERICA
24.5 MIDDLE EAST AND AFRICA
24.5.1 SOUTH AFRICA
24.5.2 EGYPT
24.5.3 BAHRAIN
24.5.4 UNITED ARAB EMIRATES
24.5.5 KUWAIT
24.5.6 OMAN
24.5.7 QATAR
24.5.8 SAUDI ARABIA
24.5.9 REST OF MEA
24.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
25 GLOBAL JANUS KINASES (JAKS) INHIBITOR DRUGS MARKET, COMPANY PROFILE
25.1 ABBVIE INC
25.1.1 COMPANY OVERVIEW
25.1.2 REVENUE ANALYSIS
25.1.3 GEOGRAPHIC PRESENCE
25.1.4 PRODUCT PORTFOLIO
25.1.5 RECENT DEVELOPMENTS
25.2 PFIZER, INC.
25.2.1 COMPANY OVERVIEW
25.2.2 REVENUE ANALYSIS
25.2.3 GEOGRAPHIC PRESENCE
25.2.4 PRODUCT PORTFOLIO
25.2.5 RECENT DEVELOPMENTS
25.3 GALAPAGOS NV
25.3.1 COMPANY OVERVIEW
25.3.2 REVENUE ANALYSIS
25.3.3 GEOGRAPHIC PRESENCE
25.3.4 PRODUCT PORTFOLIO
25.3.5 RECENT DEVELOPMENTS
25.4 THERAVANCE BIOPHARMA
25.4.1 COMPANY OVERVIEW
25.4.2 REVENUE ANALYSIS
25.4.3 GEOGRAPHIC PRESENCE
25.4.4 PRODUCT PORTFOLIO
25.4.5 RECENT DEVELOPMENTS
25.5 INCYTE/
25.5.1 COMPANY OVERVIEW
25.5.2 REVENUE ANALYSIS
25.5.3 GEOGRAPHIC PRESENCE
25.5.4 PRODUCT PORTFOLIO
25.5.5 RECENT DEVELOPMENTS
25.6 CTI BIOPHARMA CORP
25.6.1 COMPANY OVERVIEW
25.6.2 REVENUE ANALYSIS
25.6.3 GEOGRAPHIC PRESENCE
25.6.4 PRODUCT PORTFOLIO
25.6.5 RECENT DEVELOPMENTS
25.7 GSK/SIERRA ONCOLOGY, INC
25.7.1 COMPANY OVERVIEW
25.7.2 REVENUE ANALYSIS
25.7.3 GEOGRAPHIC PRESENCE
25.7.4 PRODUCT PORTFOLIO
25.7.5 RECENT DEVELOPMENTS
25.8 IMPACT BIOMEDICINES, INC., A BRISTOL-MYERS SQUIBB COMPANY.
25.8.1 COMPANY OVERVIEW
25.8.2 REVENUE ANALYSIS
25.8.3 GEOGRAPHIC PRESENCE
25.8.4 PRODUCT PORTFOLIO
25.8.5 RECENT DEVELOPMENTS
25.9 VERTEX PHARMACEUTICALS INCORPORATED
25.9.1 COMPANY OVERVIEW
25.9.2 REVENUE ANALYSIS
25.9.3 GEOGRAPHIC PRESENCE
25.9.4 PRODUCT PORTFOLIO
25.9.5 RECENT DEVELOPMENTS
25.1 ASTELLAS PHARMA INC.
25.10.1 COMPANY OVERVIEW
25.10.2 REVENUE ANALYSIS
25.10.3 GEOGRAPHIC PRESENCE
25.10.4 PRODUCT PORTFOLIO
25.10.5 RECENT DEVELOPMENTS
25.11 ACLARIS THERAPEUTICS, INC
25.11.1 COMPANY OVERVIEW
25.11.2 REVENUE ANALYSIS
25.11.3 GEOGRAPHIC PRESENCE
25.11.4 PRODUCT PORTFOLIO
25.11.5 RECENT DEVELOPMENTS
25.12 REISTONE BIOPHARMA
25.12.1 COMPANY OVERVIEW
25.12.2 REVENUE ANALYSIS
25.12.3 GEOGRAPHIC PRESENCE
25.12.4 PRODUCT PORTFOLIO
25.12.5 RECENT DEVELOPMENTS
25.13 ELI LILLY AND COMPANY
25.13.1 COMPANY OVERVIEW
25.13.2 REVENUE ANALYSIS
25.13.3 GEOGRAPHIC PRESENCE
25.13.4 PRODUCT PORTFOLIO
25.13.5 RECENT DEVELOPMENTS
26 RELATED REPORTS
27 CONCLUSION
28 QUESTIONNAIRE
29 ABOUT DATA BRIDGE MARKET RESEARCH
